Compare · LRMR vs NVO
LRMR vs NVO
Side-by-side comparison of Larimar Therapeutics Inc. (LRMR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LRMR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $188.51B, about 447.0x LRMR ($421.8M).
- NVO has been more active in the news (6 items in the past 4 weeks vs 4 for LRMR).
- NVO has more recent analyst coverage (25 ratings vs 9 for LRMR).
- Company
- Larimar Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $421.8M
- $188.51B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 4
- 6
- Recent ratings
- 9
- 25
Larimar Therapeutics Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LRMR
- Amendment: SEC Form SCHEDULE 13G/A filed by Larimar Therapeutics Inc.
- Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia
- SEC Form DEF 14A filed by Larimar Therapeutics Inc.
- SEC Form PRE 14A filed by Larimar Therapeutics Inc.
- SEC Form S-8 filed by Larimar Therapeutics Inc.
- SEC Form 10-K filed by Larimar Therapeutics Inc.
- Larimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
- Larimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S